Search | Clinical Trials Finder

Conditions: Asthma, Smoking Cessation
Interventions: Cessation Counseling; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Day and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Influenza, COVID-19, Vaccination Hesitancy
Interventions: Text message influenza vaccine reminders, Text message COVID-19 vaccine reminders, Text message influenza and COVID-19 vaccine reminders; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 6 Months to 17 Years
Enrollment: 66,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Itasca, Illinois • New York, New York • Philadelphia, Pennsylvania

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Clarithromycin, Zidovudine, Didanosine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Bethesda, Maryland

Conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions: RSVpreF 120 µg, RSVpreF 60 µg; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • Rolling Hills Estates, California + 12 more

Conditions: PANS, PANDAS, Obsessive Compulsive Disorder (OCD)
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 4 Years to 14 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Hematologic Malignancies
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Acute Upper Respiratory Infection, Signs and Symptoms
Interventions: Handheld humidifier; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Molluscum Contagiosum
Interventions: 10% East Indian sandalwood oil cream, Placebo Cream; Drug
Lead sponsor: ViroXis Corporation; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Suspected or Documented Gram-negative Bacterial Infection
Interventions: IMI/REL, Active Control, Oral Switch; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: Up to 17 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • Long Beach, California • San Diego, California + 5 more

Conditions: Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
Interventions: Angiotensin II; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Charlotte, North Carolina • Cincinnati, Ohio • San Antonio, Texas

Conditions: Complicated Intra-Abdominal Infection
Interventions: Ceftolozane/Tazobactam, Metronidazole, Meropenem, Placebo for Metronidazole; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 7 Days to 17 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Diego, California + 6 more

Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Hemophagocytic Lymphohistiocytoses, Primary Immunodeficiency Diseases, Hemoglobinopathies, Severe Aplastic Anemia, Cytopenia, Bone Marrow Failure Syndrome, Severe Chronic Active Epstein-Barr Virus Infection
Interventions: CliniMACS; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Abscess
Interventions: Bedside emergency ultrasound; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Months to 18 Years
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sepsis
Interventions: Drotrecogin alfa (activated), Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Up to 17 Years
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 23
States / cities: Birmingham, Alabama • Tucson, Arizona • Tuscon, Arizona + 20 more

Conditions: Influenza, Human
Interventions: Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 6 Months to 59 Months
Enrollment: 2,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 39
States / cities: Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 27 more

Conditions: Skin Infections, Bacterial
Interventions: Retapamulin Ointment, 1%, Placebo ointment; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Months and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 32
States / cities: Tucson, Arizona • Anaheim, California • Fresno, California + 27 more

Conditions: COVID-19
Interventions: nirmatrelvir, ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 50
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 32 more

Conditions: Bronchiolitis
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 37 Weeks to 2 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Lung Transplant, Bronchiolitis Obliterans, Obliterative Bronchiolitis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 21 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 6
States / cities: Palo Alto, California • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: Tinea Capitis
Interventions: Terbinafine hydrochloride; Drug
Lead sponsor: Novartis; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Infection, Human Immunodeficiency Virus
Interventions: DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY (DTG); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Idiopathic Scoliosis
Interventions: Bolus dose of Cefazolin, Continuous Cefazolin drip, Paraspinal muscle microdialysis catheters, Subcutaneous microdialysis catheters; Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 12 Years to 20 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]); Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Modesto, California • Westminster, California + 13 more

Conditions: Herpes Simplex
Interventions: famciclovir; Drug
Lead sponsor: Novartis; Industry
Eligibility: 1 Month to 1 Year
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 3 more

Search by objective public record fields.

Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke

Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season

The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

Antibiotic Treatment Trial for the PANDAS/PANS Phenotype

Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors

Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

A Study of LJPC-501 in Pediatric Patients With Hypotension

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections

Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Atrial and Brain Natriuretic Peptides in Bronchiolitis

Viral Triggers in Pediatric Lung Transplantation

Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

Skeletal Muscle and Adipose Tissue Study

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19

Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection